Form 8-K - Current report:
SEC Accession No. 0000950170-23-008939
Filing Date
2023-03-21
Accepted
2023-03-21 16:15:43
Documents
13
Period of Report
2023-03-16
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Document Format Files

Seq Description Document Type Size
1 8-K igms-20230316.htm   iXBRL 8-K 62745
2 EX-3.1 igms-ex3_1.htm EX-3 330471
  Complete submission text file 0000950170-23-008939.txt   560362

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT igms-20230316_lab.xml EX-101.LAB 14563
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT igms-20230316.xsd EX-101.SCH 2451
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT igms-20230316_pre.xml EX-101.PRE 10662
7 EXTRACTED XBRL INSTANCE DOCUMENT igms-20230316_htm.xml XML 5118
Mailing Address 325 E MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043
Business Address 325 E MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043 650-965-7873
IGM Biosciences, Inc. (Filer) CIK: 0001496323 (see all company filings)

EIN.: 770349194 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39045 | Film No.: 23749901
SIC: 2834 Pharmaceutical Preparations